Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study Zhenggang Ren , Jianming Xu , Yuxian Bai +37 more 2021 The Lancet Oncology 984 citations